Immatics Reports Increased Q1 2025 Loss Amid Rising R&D Costs

Immatics ( (IMTX) ) just unveiled an announcement.

On May 13, 2025, Immatics N.V. released its interim financial report for the first quarter of 2025, revealing a net loss of €39.9 million compared to a €2.2 million loss in the same period the previous year. Despite an increase in research and development expenses, the company continues to advance its pipeline of cancer immunotherapies, which may impact its future financial performance and market positioning.

The most recent analyst rating on (IMTX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Immatics stock, see the IMTX Stock Forecast page.

Spark’s Take on IMTX Stock

According to Spark, TipRanks’ AI Analyst, IMTX is a Neutral.

Immatics is experiencing strong revenue growth but faces challenges with profitability and cash flow. The balance sheet provides a solid base, though the high P/E ratio suggests overvaluation. Technical indicators show moderate momentum, leaving the stock in a neutral position with potential resistance. Overall, the stock scores moderately due to financial and valuation concerns.

To see Spark’s full report on IMTX stock, click here.

More about Immatics

Immatics N.V. operates in the biotechnology industry, focusing on the development of cancer immunotherapies. The company specializes in T-cell receptor-based therapeutics, aiming to harness the power of the immune system to target and eliminate cancer cells.

Average Trading Volume: 711,056

Technical Sentiment Signal: Sell

Current Market Cap: $554.3M

For a thorough assessment of IMTX stock, go to TipRanks’ Stock Analysis page.